Subcutaneous immunoglobulin replacement therapy with Hizentra® is safe and effective in two infants.
Hizentra® is a 20% liquid IgG product approved for subcutaneous administration in adults and children greater than 2 years of age. We report two infants less than 2 years in which administration of Hizentra® was safe and effective.